Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield(University of Birmingham), Д. А. Шапиро(University of Padua), Cathi Sciacca(Intercept Pharmaceuticals (United States)), Velimir A. Luketic(University of Padua), O. Böhm(FGK Clinical Research), Henry C. Bodhenheimer(Mount Sinai Beth Israel), Stuart C. Gordon(Henry Ford Health System), Erin Castelloe(Intercept Pharmaceuticals (United States)), T. Beecher-Jones(Intercept Pharmaceuticals (United States)), Luciano Adorini(Intercept Pharmaceuticals (United States)), Keith D. Lindor(University of Padua), Andrew L. Mason(University of Alberta), Hanns–Ulrich Marschall(University of Padua), Albert Parés(European Association for the Study of Diabetes), Michael Trauner(Medical University of Graz), Catherine Vincent(University of Padua), Kris V. Kowdley(Washington State University Spokane), Marlyn J. Mayo(The University of Texas Southwestern Medical Center)
Cited by 563
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k